ValuEngine upgraded shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) from a sell rating to a hold rating in a research report released on Friday.

IRWD has been the topic of several other reports. J P Morgan Chase & Co reiterated a neutral rating and issued a $19.00 price target (down from $20.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, July 21st. Wedbush reiterated a neutral rating and issued a $13.00 price target on shares of Ironwood Pharmaceuticals in a research note on Tuesday, May 9th. BidaskClub lowered shares of Ironwood Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, June 30th. Mizuho lifted their price target on shares of Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the company a buy rating in a research note on Tuesday, July 4th. Finally, Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a strong sell rating to a hold rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $18.13.

Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) opened at 16.16 on Friday. The company’s market capitalization is $2.42 billion. The company has a 50-day moving average of $16.17 and a 200-day moving average of $17.13. Ironwood Pharmaceuticals has a one year low of $12.48 and a one year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The business had revenue of $65.10 million during the quarter, compared to analyst estimates of $70 million. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. The firm’s quarterly revenue was up 19.7% on a year-over-year basis. On average, analysts anticipate that Ironwood Pharmaceuticals will post ($1.10) earnings per share for the current year.

WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/05/ironwood-pharmaceuticals-inc-irwd-raised-to-hold-at-valuengine.html.

In related news, insider Halley E. Gilbert sold 35,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the sale, the insider now owns 35,000 shares of the company’s stock, valued at approximately $691,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.63% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 24,051 shares of the biotechnology company’s stock worth $410,000 after buying an additional 62 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 5.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after buying an additional 648 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 8.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock worth $207,000 after buying an additional 898 shares during the period. Aperio Group LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 11.9% during the 2nd quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after buying an additional 1,410 shares during the period. Finally, Amalgamated Bank boosted its holdings in shares of Ironwood Pharmaceuticals by 9.0% during the 2nd quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after buying an additional 1,421 shares during the period. 97.95% of the stock is owned by institutional investors and hedge funds.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.